Mark Hasleton is a seasoned professional with over 20 years of global experience in biotechnology, pharmaceuticals, and medical devices. Currently serving as the VP of Clinical Trial Financing at SPRIM Global Investments and Acting Chief Executive Officer at PROTA THERAPEUTICS PTY LTD, Mark co-founded 428 Pharma in 2020. Previously, they held positions such as EU Business Operations Manager at Bristol Myers Squibb and Director Ex-US Sourcing Global Branded Products at Teva Pharmaceuticals. Mark earned a PhD in Molecular Biology from Imperial College and an MBA from Imperial College Business School. Their innovative contributions have garnered recognition, including being named among the top ten exciting innovators in biopharma by Ideapharma.
This person is not in the org chart
This person is not in any teams
This person is not in any offices